Rallying 2014

Rallying-T-shirt-2014Rallying to the challenge 2014 focused on how people with Parkinson’s (PwP) can strongly influence the effectiveness of clinical trials.

Clinical trials are essential in assessing how effective or safe treatments are as well as advancing a greater understanding about a condition.

The process of medicine development from test-tube to patient can take a decade or more, and is extremely costly to the investing company. These costs can only be recovered and converted to profit in drugs that demonstrate efficacy in phase 3 clinical trials. Sadly, new treatments are comparatively infrequent and the development of each new medicine is a significant event for the Parkinson’s community.

Historically, clinical trials in Parkinson’s have a poor success rate, with many drugs failing to show they are effective at the phase 3 stage, when the evidence for licensing a drug is assessed by the FDA and other regulators. So, the failure of a clinical trial is a major setback to a drug company involved in drug development for Parkinson’s. Failure also has implications for the patient community, depriving them of potentially effective new treatments.

Why do some clinical trials fail?
Clinical trials can be unsuccessful for numerous reasons for example; failures of trial design, recruiting people to take part, communication and information. To try to understand more about the ‘barriers’ that hinder trials from succeeding, Parkinson’s Movement developed and carried out an online survey.
The results of this survey were the focus of the discussion at Rallying to the Challenge 2014, and led to the formation of the Parkinson’s Clinical Trials Charter.

 

 

RELATED ITEMS

  • At our patient advocate Rallying to the Challenge Meeting in 2014 it was unanimously agreed in the value of developing a clinical trials charter to significantly improve communication between those taking part in trials and those running clinical trials. The Charter was developed by people living with Parkinson's and clinicians…
  • What is Rallying to the Challenge?Rallying to the Challenge, hosted by  The Cure Parkinson’s Trust and Parkinson’s Movement, brings together people with Parkinson’s and advocates from around the world to devise ways to positively impact clinical trials and research.This conference has one simple aim – to involve people living with…
  • The quiet revolution I think we all accept the notion that clinical trials are central to the development of new medicines and new treatments for Parkinson's. And it's also true that the majority of these will be conducted by the pharmaceutical industry or academic units. Both have a strong vested…
  • Trials using treatments to slow, stop or reverse Parkinson’s The Cure Parkinson's Trust manage and facilitate an innovative research programme called Linked Clinical Trials with the sole aim of bringing forward treatments that biochemically show the potential to slow, stop or reverse Parkinson's. Each year around 25 compounds are evaluated…
  • Rallying to the Challenge: Parkinson’s Movement at Grand Challenges took place on 24th and 25th September 2014 24th September 2014 9.00 Mr David Van Andel, Van Andel Institute 9.15 Jay Van Andel Award for Outstanding Achievement in Parkinson’s Research Professor Andrew Lees Challenges at a Glance: Grand Challenges Meeting 10.45…